Insider Selling: Synopsys, Inc. (NASDAQ:SNPS) Insider Sells 15,705 Shares of Stock

Synopsys, Inc. (NASDAQ:SNPS) insider Geus Aart De sold 15,705 shares of Synopsys stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $444.42, for a total transaction of $6,979,616.10. Following the sale, the insider now owns 116,671 shares in the company, valued at approximately $51,850,925.82. This represents a 11.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Synopsys Stock Performance

Synopsys stock opened at $432.46 on Thursday. Synopsys, Inc. has a 52-week low of $427.30 and a 52-week high of $624.80. The firm has a 50 day moving average price of $497.92 and a two-hundred day moving average price of $509.52. The firm has a market cap of $66.87 billion, a price-to-earnings ratio of 29.78, a PEG ratio of 3.23 and a beta of 1.16.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SNPS shares. Robert W. Baird cut their target price on shares of Synopsys from $644.00 to $630.00 and set an “outperform” rating on the stock in a research report on Thursday, December 5th. Needham & Company LLC reiterated a “buy” rating and set a $650.00 target price on shares of Synopsys in a research report on Thursday, February 27th. Rosenblatt Securities reiterated a “buy” rating and set a $660.00 target price on shares of Synopsys in a research report on Tuesday, February 25th. Piper Sandler cut their target price on shares of Synopsys from $655.00 to $653.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Finally, Wells Fargo & Company cut their target price on shares of Synopsys from $540.00 to $520.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Synopsys currently has an average rating of “Moderate Buy” and an average price target of $638.58.

Institutional Trading of Synopsys

Several hedge funds have recently modified their holdings of the stock. Centaurus Financial Inc. increased its stake in shares of Synopsys by 24.7% in the 4th quarter. Centaurus Financial Inc. now owns 561 shares of the semiconductor company’s stock valued at $272,000 after acquiring an additional 111 shares in the last quarter. Siemens Fonds Invest GmbH increased its stake in shares of Synopsys by 17.2% in the 4th quarter. Siemens Fonds Invest GmbH now owns 8,795 shares of the semiconductor company’s stock valued at $4,269,000 after acquiring an additional 1,288 shares in the last quarter. Cim LLC increased its stake in shares of Synopsys by 0.4% in the 4th quarter. Cim LLC now owns 38,744 shares of the semiconductor company’s stock valued at $18,805,000 after acquiring an additional 173 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Synopsys in the 4th quarter valued at $104,237,000. Finally, Jefferies Financial Group Inc. increased its stake in shares of Synopsys by 35.1% in the 4th quarter. Jefferies Financial Group Inc. now owns 2,557 shares of the semiconductor company’s stock valued at $1,241,000 after acquiring an additional 665 shares in the last quarter. Institutional investors own 85.47% of the company’s stock.

About Synopsys

Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.